Clinical Efficacy and Tumor Microenvironment Influence in a Dose-Escalation Study of Anti-CD19 Chimeric Antigen Receptor T Cells in Refractory B-Cell Non-Hodgkin's Lymphoma.

CONCLUSIONS: JWCAR029was effective and safe in treating refractory B-NHL. The composition of the tumor microenvironment has a potential impact inCAR T therapy response.
PMID: 31444250 [PubMed - as supplied by publisher]

Source: Clinical Cancer Research - August 22, 2019 Category: Cancer & Oncology Authors: Yan Z, Li L, Wang W, OuYang B, Cheng S, Wang L, Wu W, Xu PP, Muftuoglu M, Hao M, Yang S, Zhang M, Zheng Z, Li J, Zhao WL Tags: Clin Cancer Res Source Type: research